medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2013, Número 2

<< Anterior Siguiente >>

Dermatología Cosmética, Médica y Quirúrgica 2013; 11 (2)


Dermatitis herpetiforme con patrón fibrilar en inmunofluorescencia: reporte de un caso y revisión de literatura

López ZJB, Romo SC

Idioma: Español
Referencias bibliográficas: 31
Paginas: 112-116
Archivo PDF: 182.36 Kb.


RESUMEN

Dermatitis herpetiforme (DH) es una rara enfermedad ampollar autoinmune, de etiología multifactorial, que suele considerarse una manifestación cutánea de hipersensibilidad al gluten dietético. En su abordaje diagnóstico figura la inmunofluorescencia directa (IFD) de piel perilesional, típicamente con patrón granular en papilas o membrana basal. Sin embargo, también se ha descrito un patrón fibrilar relativamente raro que suele relacionarse con una presentación atípica de la enfermedad, seronegatividad en pruebas de anticuerpos e incluso ausencia de haplotipo HLA-B8/DR3DQ2. Este artículo describe un caso DH típico con IFD en patrón fibrilar y hace una breve revisión de la literatura.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Duhring LA. “Dermatitis Herpetiformis”. J Am Med Assoc 1884; 3: 225-229.

  2. Hull CM, Zone JJ. “Dermatitis Herpetiformis and linear IgA bullous dermatosis”. En: Bolognia JL, Jorizo JL, Schaffer JV. Dermatology, 3a ed., vol. 1, Elsevier-Saunders 2012: 447-452.

  3. Cormane RH. “Immunofluorescent studies of the skin in lupus erythematosus and other diseases”. Pathol Eur 1967; 2: 170-180.

  4. Van der Meer JB. “Granular deposits of immunoglobulin in the skin of patient with dermatitis herpetiformis: An immunofluorescent study”. Br J Dermatol 1969; 81: 493-503.

  5. Bolotin D, Petronic-Rosic V. “Dermatitis herpetiformis: Part I and Part II”. J Am Acad Dermatol 2011; 1017-1033.

  6. Karpati S. “An Exception Within the Group of Autoimmune Blistering Diseases: Dermatitis Herpetiformis, the Gluten-Sensitive Dermopathy”. Immunol Allergy Clin N Am 2012: 32: 255-262.

  7. Caproni M, Antiga E, Melani L, Fabbri P. “Guidelines for the diagnosis and treatment of dermatitis herpetiformis”. J Eur Acad Dermatol Venereol 2009; 23: 633-638.

  8. Iranzo-Fernández P. “Dermatitis herpetiforme. Patogenia, diagnóstico y tratamiento”. Med Cutan Iber Lat Am 2010; 38(1): 5-15.

  9. Rose C, Ambruster FP, Ruppert J, Igl BW, Zillikens D, Shimanovich I. “Autoantibodies against epidermal tranglutaminase are a sensitive diagnostic marker in patients with dermatitis herpetiformis on a normal or gluten-free diet”. J Am Acad Dermatol 2009; 61: 39-43.

  10. Alonso-Llamazares J, Gibson LE, Rogers RS. “Clinical, pathologic, and immunopathologic features of dermatitis herpetiformis: review of the Mayo Clinic experience”. Int J Dermatol 2007; 46: 910-919.

  11. Oxentenko AS, Murray JA. “Celiac disease and dermatitis herpetiformis: the spectrum of gluten-sensitive enteropathy”. Int J Dermatol 2003; 42: 585-587.

  12. Smith JB, Tulloch JE, Meyer LJ, Zone JJ. “The incidence and prevalence of dermatitis herpetiformis in Utah”. Arch Dermatol 1992; 128: 1608- 1610.

  13. Fry L. “Dermatitis herpetiformis: problems, progress and prospects”. Eur J Dermatol 2002; 12: 523-531.

  14. Cunningham MJ, Zone JJ. “Thyroid abnormalities in dermatitis herpetiformis; prevalence of clinical thyroid disease and thyroid autoantibodies”. Ann Intern Med 1985; 102: 194-196.

  15. Reunala T, Collin P. “Diseases associated with dermatitis herpetiformis”. Br J Dermatol 1997; 136: 315-318.

  16. Grainge MJ, West J, Solaymani-Dodaran M, Card TR, Logan RFA. “The long-term risk of malignancy following a diagnosis of coeliac disease or dermatitis herpetiformis: a cohort study”. Aliment Pharmacol Ther 2012; 35: 730-739.

  17. Askling J, Linet M, Gridley G, Halstensen TS, Ekstrom K, Ekbom A. “Cancer incidence in a population-based cohort of individuals hospitalized with celiac disease or dermatitis herpetiformis”. Gastroenterology 2002; 123: 1428-1435.

  18. Herrero-González JE. “Clinical Guidelines for the diagnosis and treatment of dermatitis herpetiformis”. Actas Dermosifiliogr 2010; 101(10): 820-826.

  19. M. Bowszyc-Dmochowska, A. Seraszek, E. Kaczmarek, Gornowicz J, Dmochowski M. “Low strength of correlation between the intensity of neutrophil elastase expression in lesional skin and the level of serum IgA antibodies to epidermal transglutaminase in dermatitis herpetiformis”. Dermatol Kliniczna 2008, 10 (3): 135-137.

  20. Bonciolini V, Bonciani D, Verdelli A, D’Errico A, Antiga E, Fabbri P, et al. “Newly Described Clinical and Immunopathological Feature of Dermatitis Herpetiformis”. Clin Develop Immunol 2012: 1-5.

  21. Fuertes I, Mascaro JM, Bombi JM, Iranzo P. A “Retrospective Study of Clinical, Histological, and Immunological Characteristics in Patients With Dermatitis Herpetiformis. The Experience of Hospital Clinic de Barcelona, Spain between 1995 and 2010 and a Review of the Literature”. Actas Dermosifiliogr 2011; 102(9): 699-705.

  22. Warren SJP, Cockerell CJ. “Characterization of a subgroup of patients with dermatitis herpetiformis with nonclassical histologic features”. Am J Dermatopathol 2002; 24: 305.

  23. Van L, Bronwning JC, Krishnan RS, Kenner-Bell BM, Hsu S. “Dermatitis herpetiformis: Potential for confusion with linear IgA bullous dermatosis on direct immunofluorescence”. Dermatol Online J 2008, 14 (1): 21.

  24. Sousa L, Bajanca R, Cabral J, Fiadeiro T. “Dermatitis herpetiformis: Should direct immunofluorescence be the only diagnostic criterion?” Pediatrdermatol 2002, 19(4): 336-339.

  25. Clements SE, Stefanato CM, Bhogal B, Groves RW. “Atypical dermatitis herpetiformis with fibrillar IgA deposition: CPC-8”. Br J Dermatol 2007; 157: 17.

  26. Dieterich W, Laag E, Bruckner-Tuderman L, et al. “Antibodies to tissue transglutaminase as serologic markers in patients with dermatitis herpetiformis”. J Invest Dermatol 1999; 113(1): 133-136.

  27. KoCJ, Colegio OR, Moss JE, McNiff JM. “Fibrillar IgA deposition in dermatitis herpetiformis – an underreported pattern with potential clinical significance”. J Cutan Pathol 2010; 37: 475-477.

  28. KawanaS, Segawa A. “Confocal laser scanning microscopic and immunoelectron microscopic studies of the anatomical distribution of fibrillar IgA deposits in dermatitis herpetiformis”. Arch Dermatol 1993; 129(4): 456-459.

  29. Vaughan-Jones SA, Bhogal BS, Black MM. Fibrillar IgA deposition may be associated with atypical dermatitis herpetiformis – a report of two cases”. J Eur Acad Dermatol Venereol 1996; 7: 270-278.

  30. Shibahara M, Nanko H, Shimizu M, Kanda M, Kubo M, Ikeda M, et al. “Dermatitis herpetiformis in Japan: an update”. Dermatology 2002; 204: 37.

  31. Leonard JN, Haffenden GP, Fry L. “Dermatitis herpetiformis”. En: Beutner EH, Chorzelski TP, Kumar V. Immunopathology of the Skin, 3a ed., New York, John Wiley & Sons, 1987: 433-453.




2020     |     www.medigraphic.com